Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12622000349741
Ethics application status
Approved
Date submitted
15/02/2022
Date registered
25/02/2022
Date last updated
31/01/2023
Date data sharing statement initially provided
25/02/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
'One injection vs. three': Clinical evaluation of a single, high dose subcutaneous infusion of benzathine penicillin G for treatment of syphilis (SCIP Syphilis)
Query!
Scientific title
'One injection vs. three': Evaluation of the safety and tolerability of a single, high dose subcutaneous infusion of benzathine penicillin G for treatment of syphilis (SCIP Syphilis)
Query!
Secondary ID [1]
306438
0
None
Query!
Universal Trial Number (UTN)
U1111-1271-3685
Query!
Trial acronym
SCIP Syphilis
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Syphilis
325278
0
Query!
Condition category
Condition code
Infection
322677
322677
0
0
Query!
Sexually transmitted infections
Query!
Infection
322678
322678
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
7.2 MU (13.8mL) benzathine penicillin G (BPG) as Bicillin® L-A given as a single (once-only) subcutaneous infusion (over 10 - 30 minutes) in adults for treatment of non-central nervous system (CNS) syphilis infections.
Query!
Intervention code [1]
322871
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
330474
0
Safety and tolerability of 7.2MU Bicillin® L-A given by subcutaneous infusion for treatment of non-CNS syphilis infection, assessed as a composite using adverse events, numerical pain scoring and local skin irritation.
Adverse events will be collected by participant self-report (during phone calls and in-person reviews) and clinical examination during the follow up visits. Based on prior results from healthy human volunteers (n=24), common adverse events following subcutaneous infusion included swelling, bruising and changes to pigmentation at site of injection.
Pain scoring will be measured using the numeric rating scale (NRS), which is a valid method for recording pain in this setting. The NRS has been validated in adults for recording pain; the scoring system has 11 (0-10) different values anchored by terms describing pain severity extremes: 0=none, 1-3=mild, 4-6=moderate, and 7-10=severe. A score of 10 indicates the worst pain imaginable.
Local skin irritation will be monitored using a participant questionnaire (modified Skindex-16) regarding symptoms of pain, character, itchiness, pallor or erythema, bleeding, and heat at the injection site.
Query!
Assessment method [1]
330474
0
Query!
Timepoint [1]
330474
0
Adverse events will be assessed from time of infusion and each follow up at day 1, 2, 3, 7. 14 and weeks 3, 6, 12, 24 post infusion.
Pain scoring will be taken at: infusion completion, day 1, 2, 3, 7 and 14 post infusion.
Participants will complete a modified Skindex-16 questionnaire on days 1, 2, 3, 7 and 14 post infusion.
Query!
Secondary outcome [1]
406378
0
Need for repeat treatment for syphilis infection within 6 months post infusion, due to treatment failure (assessed using treponemal serology and need for repeat treatment determined by the treating practitioner)
Query!
Assessment method [1]
406378
0
Query!
Timepoint [1]
406378
0
Treponemal serology (specific and non-specific) at recruitment, and weeks 3, 6, 12 and 24 post infusion.
Query!
Secondary outcome [2]
406384
0
Plasma penicillin concentration at 21 days post 7.2 MU Bicillin® L-A administered by a single subcutaneous infusion as a surrogate predictor for treatment efficacy
Query!
Assessment method [2]
406384
0
Query!
Timepoint [2]
406384
0
Plasma penicillin concentration at 21 days post-infusion
Query!
Secondary outcome [3]
406385
0
Change in titre of non-treponemal specific serology as a surrogate marker for treatment efficacy
Query!
Assessment method [3]
406385
0
Query!
Timepoint [3]
406385
0
non-treponemal specific serology (RPR) at 24 weeks post-infusion
Query!
Secondary outcome [4]
406386
0
Time above plasma concentration of penicillin of 0.018mg/mL (for T. pallidum) post infusion of 7.2 MU of BPG
Query!
Assessment method [4]
406386
0
Query!
Timepoint [4]
406386
0
Plasma penicillin concentration samples will be taken at baseline, weeks 3, 6 and 12 following infusion
Query!
Secondary outcome [5]
406477
0
Qualitative exploration of patient's experience and perception of receiving subcutaneous infusion using semi-structured face-to-face interviews using scripted questions.
Query!
Assessment method [5]
406477
0
Query!
Timepoint [5]
406477
0
Qualitative interviews will be conducted immediately following infusion, at weeks 3 and 24 post-infusion follow up visits
Query!
Eligibility
Key inclusion criteria
(a) Males and non-pregnant females aged older than 18 years
(b) Diagnosis of syphilis infection (made by a medical practitioner) AND requiring treatment with BPG in the form of Bicillin® L-A. This is defined as follows:
i. Positive treponemal serology (Total antibody AND TPPA)
ii. Primary syphilis (diagnosed clinically) with PCR confirmation of T. pallidum
(c) No prior documented allergy to penicillin.
(d) No history of anaphylactic reaction to cephalosporin antibiotics.
(e) Participants who are considered likely to adhere to the trial guidelines for the duration of the trial and are willing and deemed reliable to attend follow up appointments as outlined in the protocol.
(f) Able to provide informed consent in accordance with Good Clinical Practice.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
(a) Pregnant or breastfeeding females
(b) Diagnosis of neurosyphilis (CNS, otic or optic syphilis) made by a medical practitioner
(c) Known hypersensitivity or contraindication to use of penicillin.
(d) Existing dermatological conditions or other abnormalities (e.g., extensive scarring) that may affect skin integrity at the site of injection, especially abdomen or lateral hips.
(e) Presence of significant co-morbidities which is likely to impact patient’s participation the study, as assessed by a medical practitioner
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
A pragmatic sample size of 40 is chosen to allow for demonstration of tolerability and safety in a target patient population with non-CNS syphilis infection. Assuming that 95% of dosed participants will have penicillin concentrations >18ng/mL at 21 days (expected based on prior pharmacokinetic study in healthy adults), a sample size of at least 33 will estimate the expected proportion (of participants with penicillin concentrations >18ng/mL at 21 days) with 7.5% absolute precision and 95% confidence.
NONMEM compiler will be used for pharmacokinetic analysis. Given the sparse pharmacokinetic sampling planned, the observed concentrations will be assessed with respect to population pharmacokinetic model derived from a previous study of SC administration in healthy volunteers.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/03/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/03/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
1/09/2024
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
0
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
21743
0
Fremantle Hospital and Health Service - Fremantle
Query!
Recruitment postcode(s) [1]
36797
0
6160 - Fremantle
Query!
Funding & Sponsors
Funding source category [1]
310785
0
Government body
Query!
Name [1]
310785
0
Australian Department of Health (Medical Research Future Fund
Query!
Address [1]
310785
0
GPO Box 1421, Canberra ACT 2601 Australia
Query!
Country [1]
310785
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
South Metropolitan Health Service
Query!
Address
14 Barry Marshall Parade, Murdoch, WA 6150
Query!
Country
Australia
Query!
Secondary sponsor category [1]
312035
0
None
Query!
Name [1]
312035
0
Query!
Address [1]
312035
0
Query!
Country [1]
312035
0
Query!
Other collaborator category [1]
282161
0
University
Query!
Name [1]
282161
0
Curtin University
Query!
Address [1]
282161
0
Kent St, Bentley, WA 6102
Query!
Country [1]
282161
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
310359
0
South Metropolitan Health Service Human Research Ethics Committee
Query!
Ethics committee address [1]
310359
0
Level 2, Education Building, Fiona Stanley Hospital
14 Barry Marshall Parade
Murdoch, Western Australia 6150
Australia
Query!
Ethics committee country [1]
310359
0
Australia
Query!
Date submitted for ethics approval [1]
310359
0
30/11/2021
Query!
Approval date [1]
310359
0
23/12/2021
Query!
Ethics approval number [1]
310359
0
RGS5165
Query!
Summary
Brief summary
Australia is currently in the midst of a syphilis epidemic which began a decade ago. Benzathine penicillin G (BPG) is the treatment of choice for non-CNS syphilis infections. Primary, secondary or early latent syphilis is treated with 2.4 million units (MU) of BPG, while late latent syphilis requires 2.4 MU weekly for 3 weeks in total. BPG is typically administered by IM injection which is associated with significant pain and distress in the recipient. This has been shown to negatively impact adherence, especially where multiple doses are indicated.
Subcutaneous (SC) administration of BPG is a potentially more efficacious alternative to IM injection. Prior work done by our group in healthy adult volunteers have demonstrated acceptable tolerability and a superior pharmacokinetic profile.
Our study aims to demonstrate the safety and tolerability of a single 7.2MU dose of BPG given as a subcutaneous infusion for treatment of syphilis. Secondary objectives are to demonstrate efficacy of SC BPG and estimate duration that plasma penicillin concentrations remain above the target of 18mg/mL. Primary outcome is the assessment of safety and tolerability including serious adverse events or reactions. Secondary outcomes are the change in nontreponemal specific serology titre at 6 months, plasma penicillin concentrations at 3 weeks and proportion of patients with treatment failure requiring re-treatment at 6 months.
We will recruit 40 adult patients with confirmed syphilis infection from those referred to the sexual health service at Fremantle Hospital. The study will also incorporate a qualitative component exploring patient's experience and perception of receiving subcutaneous infusion. Participants will be followed up for 6 months from day of treatment.
If we are successful in demonstrating safety, tolerability and efficacy of SC high dose penicillin in non-CNS syphilis infections, this has the potential to radically transform the treatment paradigm.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
117374
0
A/Prof Laurens Manning
Query!
Address
117374
0
The University of Western Australia (M582), 35 Stirling Highway, Crawley, WA 6009, Australia
Query!
Country
117374
0
Australia
Query!
Phone
117374
0
+61861511156
Query!
Fax
117374
0
Query!
Email
117374
0
[email protected]
Query!
Contact person for public queries
Name
117375
0
Dr Thel Hla
Query!
Address
117375
0
Fiona Stanley Hospital, Robin Warren Drive, Murdoch, WA 6150
Query!
Country
117375
0
Australia
Query!
Phone
117375
0
+61863191254
Query!
Fax
117375
0
Query!
Email
117375
0
[email protected]
Query!
Contact person for scientific queries
Name
117376
0
Dr Thel Hla
Query!
Address
117376
0
Fiona Stanley Hospital, Robin Warren Drive, Murdoch, WA 6150
Query!
Country
117376
0
Australia
Query!
Phone
117376
0
+61863191254
Query!
Fax
117376
0
Query!
Email
117376
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF